Emergent BioSolutions Q3 2026 Earnings: Revenue Falls 52% as Margins Contract

Emergent BioSolutions (NYSE: EBS) reported Q3 2026 revenue of $110.0 million, down 52% from $231.1 million, while diluted EPS fell to a loss of $0.64 from earnings of $0.91. Lower smallpox medical countermeasure, BAT, and U.S. naloxone sales pushed GAAP gross margin down to 14% and adjusted EBITDA to a $4.6 million loss.

Core Financial Results

Product sales declined by $114.5 million, accounting for most of the $121.1 million decrease in total revenue. Cost reductions did not keep pace: total operating expenses declined only 5% to $147.3 million, contributing to the swing from a quarterly profit to a loss.

Dollar amounts are in millions except per-share data.

Adjusted results are non-GAAP. Beginning in Q1 2026, Emergent revised its adjusted calculations to exclude stock-based compensation and recast the 2025 comparisons on the same basis.

Product and Segment Performance

Anthrax products were the only major revenue category to increase, benefiting from the timing of U.S. government CYFENDUS purchases. That gain only partly offset declines in naloxone, smallpox products, and BAT.

Naloxone revenue was pressured by lower U.S. over-the-counter NARCAN sales and an unfavorable price-volume mix in public-interest channels. Higher Canadian sales of branded NARCAN provided a partial offset.

Smallpox MCM revenue declined because of the timing of U.S. government ACAM2000 purchases and lower CNJ-016 sales, including fewer international sales. Higher U.S. government TEMBEXA sales provided a partial offset. Other-product revenue fell primarily because of the timing of U.S. government BAT purchases.

Services revenue decreased because of reduced production activity at the Winnipeg facility. Contracts and grants revenue also declined as Emergent performed less Ebanga-related development work.

Lower Volumes and Sales Mix Compressed Margins

The MCM Products segment generated $59.4 million of revenue, down 58%, while its cost of sales increased 5% to $40.1 million. An unfavorable product mix and lower production volumes reduced fixed-cost absorption, sending the segment’s GAAP gross margin to 19% from 68%. Its non-GAAP adjusted gross margin fell to 39% from 74%.

Commercial Products revenue declined 42% to $43.5 million. The segment’s GAAP gross margin decreased to 26% from 31%, while adjusted gross margin fell to 32% from 43%, largely because of the unfavorable price and volume mix for OTC NARCAN in U.S. channels.

At the company level, cost of product and service sales declined only 6%, despite the 52% revenue contraction. R&D expense fell 30% to $9.4 million, but SG&A increased 20% to $46.5 million. The SG&A comparison reflected a litigation insurance reimbursement recorded in the prior-year quarter and severance costs associated with the August 2026 restructuring plan.

Capital expenditures were $3.3 million, compared with $3.4 million a year earlier. Emergent also completed the repurchase of $75 million in aggregate principal amount of senior unsecured notes.

2026 Guidance

Emergent lowered its full-year revenue, adjusted net income, and adjusted EBITDA ranges. It also widened the potential GAAP net loss while raising adjusted gross margin guidance by three percentage points at both ends of the range.

Dollar amounts are in millions.

The revised ranges indicate weaker expected revenue and adjusted profit dollars despite the higher expected adjusted margin rate.

Management Commentary

President and CEO Joe Papa said the quarter was driven by Emergent’s biodefense, medical countermeasure, and naloxone portfolios. Management remains focused on improving operating performance, reducing debt, strengthening quality and compliance, and executing its multi-year turnaround.

The company implemented restructuring measures intended to reduce costs and align resources with current operating needs, including the creation of a new Growth organization. It also announced an approximately $24 million CYFENDUS contract modification and a Canadian government standing offer for NARCAN Nasal Spray.

Emergent disclosed that CFO Rich Lindahl will retire effective December 31, 2026, and remain a part-time adviser through March 31, 2027. Treasurer Frank Vargo is scheduled to become interim CFO on January 1, 2027.

Recent Insider Transactions

The six most recent reported sales had a combined transaction value of approximately $561,049. All were reported as direct holdings; the records alone do not establish the insiders’ reasons for selling.

Four additional records dated April 30, 2026, involved zero-price stock awards to directors rather than open-market purchases.

Risks Investors Should Watch

• Government procurement timing: Anthrax, smallpox, and BAT revenue can vary substantially based on annual purchase options, government funding, order timing, and deliveries. This was a major source of the quarter’s product-level volatility.
• Naloxone price and volume pressure: An unfavorable mix in U.S. OTC NARCAN channels reduced both Commercial Products revenue and margins. Continued pressure could limit the segment’s recovery.
• Fixed-cost absorption: Lower MCM volumes left manufacturing costs spread across a smaller revenue base, contributing to the sharp decline in segment margins.
• Turnaround execution: Emergent is restructuring while SG&A increased during the quarter. The company must convert its cost initiatives into sustained operating improvements.
• Reduced full-year outlook: The lowered revenue and adjusted EBITDA ranges leave the company with weaker expected full-year profit dollars, even though adjusted gross margin guidance increased.

Summary

Emergent BioSolutions’ Q3 2026 results reflected a steep decline in government-timed MCM sales and continued pressure on U.S. naloxone revenue. Higher anthrax sales were insufficient to offset the broader contraction, while unfavorable mix and weak fixed-cost absorption sharply reduced margins. Execution of the restructuring plan, NARCAN pricing and volume trends, government order timing, and delivery against the revised 2026 guidance are the principal areas to monitor.